Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaEngine Inc

Full company profile

uuid000hnz7

Namestring
PharmaEngine Inc
Legal namestring
PharmaEngine Inc.
Company typeenum
Public
Founded yearint
2003
Descriptiontext

PharmaEngine Inc. is a Taiwan-incorporated, publicly listed (Taiwan Stock Exchange: TWO:4162) biopharmaceutical company founded in February 2003 that operates under a "Virtual Pharmaceutical Company" business model. The company focuses on oncology drug development and commercialization, leveraging international strategic alliances to minimize capital expenditure on manufacturing and large-scale commercial infrastructure. Headquartered in Taipei with 33 employees as of the 2024 Annual Report, PharmaEngine is led by President & CEO Hong-Ren Wang, Ph.D., and Chairperson Jan-Yau Hsu. The company markets ONIVYDE® (liposomal irinotecan), a topoisomerase I inhibitor approved in over 50 countries for metastatic pancreatic cancer in both second-line (post-gemcitabine) and first-line (NALIRIFOX regimen) settings.

Revenue is generated primarily through royalties and milestone payments from licensing partners Ipsen (US/Canada commercialization) and Servier (global ex-US/Canada/Taiwan commercialization), supplemented by direct product sales in Taiwan through PharmaEngine's own sales organization and an exclusive Taiwan distribution arrangement for LIPORAXEL® (oral paclitaxel) with Haihe Biopharma. In February 2025 the company received a US$50 million milestone payment from Ipsen after ONIVYDE's 2024 sales in Europe and Asia triggered the second sales milestone. The R&D pipeline comprises PEP07, a brain-penetrant CHK1 inhibitor licensed from Sentinel Oncology (UK) currently in Phase I for hematologic cancers (AML, MCL) and solid tumors, and PEP08, a second-generation MTA-cooperative PRMT5 inhibitor discovered via XtalPi Holdings' AI- and robotics-powered platform that began Phase I dosing in October 2025 as PharmaEngine's first internally developed clinical asset. A second synthetic lethality program has been initiated under the expanded XtalPi partnership.

The company holds 19 in-licensed invention patents plus 1 independently granted patent and 9 pending applications, along with 14 registered trademarks. PharmaEngine is ISO 27001:2022 certified (renewed January 2026), complies with GMP/GDP/GLP/GCP quality frameworks, and operates under a board structure with representatives from the Taiwan National Development Fund, TTY Biopharm, and independent directors with government and academic backgrounds. In 2025 the company was recognized among Taiwan's Best-In-Class companies by the Taiwan Institute of Directors, ranking first in Top 10 Profit Champions and second in Top 10 Growth Companies.

Short descriptiontext

PharmaEngine Inc. is a Taiwan-listed virtual biopharmaceutical company that develops and commercializes precision oncology therapies, anchored by the global ONIVYDE franchise (liposomal irinotecan, approved in 50+ countries for metastatic pancreatic cancer) and an emerging pipeline of PRMT5 and CHK1 inhibitors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, precision cancer therapies, liposomal drug delivery, synthetic lethality research, virtual pharmaceutical company
Industry1 code
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1ONIVYDE Royalties and Milestone Payments
TypeLicensing Royalties
Description

PharmaEngine receives royalties and milestone payments from licensing partners Ipsen (US/Canada) and Servier (global markets excluding US, Canada, Taiwan) based on ONIVYDE sales and achievement of development/regulatory milestones. In 2025, PharmaEngine received US$50 million milestone payment for ONIVYDE's 2024 sales in Europe and Asia reaching the second sales milestone.

pharmaengine.com
2ONIVYDE Product Sales (Taiwan)
TypeHardware Sales
Description

PharmaEngine handles direct commercialization of ONIVYDE in Taiwan, generating product revenue through its own sales and marketing efforts.

pharmaengine.com
3LIPORAXEL Distribution (Taiwan)
TypeHardware Sales
Description

PharmaEngine holds exclusive distribution rights for LIPORAXEL (paclitaxel oral solution) in Taiwan, handling local NDA filing, sales, and marketing, creating an additional product revenue stream.

pharmaengine.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmaEngine develops and commercializes precision oncology therapies using a Virtual Pharmaceutical Company model. Its commercial product ONIVYDE® is a liposomal irinotecan formulation approved in 50+ countries for metastatic pancreatic adenocarcinoma. The pipeline includes PEP07 (CHK1 inhibitor, licensed from Sentinel Oncology) and PEP08 (first in-house developed PRMT5:MTA inhibitor, co-developed with XtalPi's AI platform), both in Phase I trials. PharmaEngine also distributes LIPORAXEL® (oral paclitaxel) in Taiwan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NAPOLI-3 Phase III trial: NALIRIFOX showed statistically significant improvement in overall survival (median OS 11.1 vs 9.2 months, HR=0.83, p=0.04) and progression-free survival (median PFS 7.4 vs 5.6 months, HR=0.69, p<0.0001) versus nab-paclitaxel+gemcitabine in previously untreated metastatic PDAC
+2 more records
Product overview1 text field

PharmaEngine Inc operates as a Virtual Pharmaceutical Company focused on oncology drug development and commercialization. The company's portfolio consists of one commercial product (ONIVYDE®) and multiple pipeline candidates in clinical development. ONIVYDE® is a liposomal irinotecan formulation for pancreatic cancer treatment marketed globally through partnerships with Ipsen and Servier. The R&D pipeline includes PEP08, a first-in-house developed PRMT5 inhibitor targeting MTAP-deleted cancers currently in Phase I trials, and PEP07, an oral CHK1 inhibitor licensed from Sentinel Oncology also in Phase I trials for hematological and solid tumors. Additionally, PharmaEngine distributes LIPORAXEL® (paclitaxel oral solution) in Taiwan under a partnership with Haihe Biopharma.

Product and service2 records
1ONIVYDE® (Irinotecan liposome injection)
CategoryCommercial oncology product (liposomal chemotherapy)
Description

Liposomal formulation of irinotecan (a topoisomerase I inhibitor) encapsulated in nanoparticles that accumulate in tumors and release the drug slowly. Approved for treatment of metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin after disease progression following gemcitabine-based therapy (second-line) and as first-line therapy in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen). Marketed globally through partners Ipsen (US/Canada) and Servier (rest of world) and directly by PharmaEngine in Taiwan.

2PEP08 (PRMT5:MTA inhibitor)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-01
Description

XtalPi and PharmaEngine partnership enabled discovery of PEP08, a next-generation PRMT5 inhibitor using XtalPi's AI- and robotics-powered platform. PEP08 received clinical clearance in June 2025 and began enrollment in Phase I solid tumor trial in October 2025. Partnership has expanded to initiate a second synthetic lethality project targeting a different undisclosed mechanism. XtalPi reported RMB 802.6 million revenue in 2025 (201.2% increase) driven by collaborations including the PharmaEngine partnership.

2Haihe Biopharma / Shanghai RMX Biopharma Co. Ltd.
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-04
Description

PharmaEngine entered an exclusive distribution agreement for LIPORAXEL (paclitaxel oral solution) in Taiwan. PharmaEngine is solely responsible for NDA filing, sales, and marketing of LIPORAXEL in Taiwan. LIPORAXEL is developed by Daehwa Pharmaceutical (South Korea) using DH-LASED drug delivery platform and distributed in Taiwan through Haihe's subsidiary Shanghai RMX Biopharma.

pharmaengine.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-03-01
Description

Servier is responsible for global commercialization of ONIVYDE outside of US, Canada, and Taiwan. In March 2024, Servier obtained EMA CHMP positive opinion and Taiwan TFDA approval for ONIVYDE NALIRIFOX as first-line treatment for metastatic pancreatic adenocarcinoma. PharmaEngine receives royalties and milestone payments from Servier's sales outside Taiwan.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-13
Description

Ipsen holds exclusive commercialization rights for ONIVYDE in the US and Canada for current and all potential future indications. On February 13, 2024, Ipsen received US FDA approval for ONIVYDE (NALIRIFOX) as first-line treatment for metastatic PDAC. PharmaEngine receives royalties and milestone payments from Ipsen based on net sales and achievement of development milestones.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-01
Description

PharmaEngine exercised option for worldwide exclusive license for PEP07 (CHK1 inhibitor) from Sentinel Oncology in September 2022. PEP07 is undergoing Phase I clinical trials for hematologic cancers (AML, MCL) and solid tumors. Sentinel Oncology eligible to receive up to US$140.5 million in upfront, development, regulatory and sales milestones plus tiered royalties on worldwide net product sales.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-03-05
Description

Partnership for PEP503 (NBTXR3) in Asia-Pacific was terminated in March 2021. PharmaEngine granted back to Nanobiotix exclusive rights for development and commercialization of NBTXR3 in Asia-Pacific region. PharmaEngine is entitled to receive US$12.5 million in milestone payments and tiered royalties on net product sales in the region upon achievement of certain milestones.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

Daehwa Pharmaceutical (South Korea) developed LIPORAXEL using its DH-LASED (Lipid Self-Emulsified Drug Delivery) technology platform. Shanghai RMX Biopharma (Haihe subsidiary) in-licensed rights for development, manufacturing, and commercialization in China, Taiwan, Hong Kong, and Thailand. PharmaEngine holds exclusive distribution rights for Taiwan.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Ipsen is PharmaEngine's exclusive commercialization partner for ONIVYDE in the US and Canada and a broader specialty oncology incumbent. Both companies operate in the same oncology pharmaceutical space and have a direct economic relationship through ONIVYDE royalties and milestones.

TypeBroad incumbent
Description

Servier is PharmaEngine's global commercialization partner for ONIVYDE outside the US, Canada, and Taiwan, and is a major European pharmaceutical company with significant oncology operations. Both companies share direct economics on ONIVYDE sales outside the named territories.

TypeDirect peer
Description

Nuvectis Pharma is a US clinical-stage precision oncology company developing a PRMT5 inhibitor (NUV-1516) for MTAP-deleted and other cancers. It is a direct competitor to PharmaEngine's PEP08 in the same target class and indication.

TypeDirect peer
Description

Cardiff Oncology is developing onvansertib, a CHK1/PLK1 inhibitor, in metastatic colorectal and other cancers. It is a direct competitor to PharmaEngine's PEP07 in the CHK1 inhibitor space and a similarly-sized clinical-stage oncology company.

TypeDirect peer
Description

IDEAYA Biosciences is a clinical-stage synthetic lethality and precision oncology company developing MAT2A and PRMT5 inhibitors (e.g., IDE397) for MTAP-deleted tumors. It is a direct competitor to PharmaEngine's PEP08 in the synthetic lethality oncology space.

TypeDirect peer
Description

Foghorn Therapeutics is a clinical-stage company developing a synthetic lethality platform targeting chromatin regulatory biology in oncology, including programs potentially relevant to PRMT5/MTAP biology. It is comparable to PharmaEngine's synthetic lethality R&D focus.

TypeDirect peer
Description

Repare Therapeutics is a clinical-stage precision oncology company building a synthetic lethality platform targeting DDR and related mechanisms (e.g., PKMYT1, ATR). Its synthetic lethality and DDR focus is directly comparable to PharmaEngine's PEP07 (CHK1/DDR) and PEP08 (synthetic lethality) programs.

TypeRegional player
Description

TTY Biopharm is a Taiwan-based specialty pharmaceutical company with oncology and specialty drug operations and is a meaningful shareholder in PharmaEngine. It is a regional Taiwan peer with overlapping cancer drug distribution and development interests.

TypeBroad incumbent
Description

PharmaMar is a European specialty oncology biopharmaceutical company developing and commercializing marine-derived oncology drugs. Both companies are specialty oncology players relying on licensing/partnerships for global reach.

TypeOthers
Description

XtalPi is PharmaEngine's strategic partner for AI- and robotics-powered small-molecule discovery that produced PEP08. It is an enabling/technology peer — comparable not as a competitor but as a closely tied discovery collaborator in the AI-enabled drug discovery ecosystem.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaEngine Inc

Oncology Pharmaceuticalspharmaengine.com

PharmaEngine Inc. is a Taiwan-listed virtual biopharmaceutical company that develops and commercializes precision oncology therapies, anchored by the global ONIVYDE franchise (liposomal irinotecan, approved in 50+ countries for metastatic pancreatic cancer) and an emerging pipeline of PRMT5 and CHK1 inhibitors.

What PharmaEngine Inc does

PharmaEngine Inc. is a Taiwan-incorporated, publicly listed (Taiwan Stock Exchange: TWO:4162) biopharmaceutical company founded in February 2003 that operates under a "Virtual Pharmaceutical Company" business model. The company focuses on oncology drug development and commercialization, leveraging international strategic alliances to minimize capital expenditure on manufacturing and large-scale commercial infrastructure. Headquartered in Taipei with 33 employees as of the 2024 Annual Report, PharmaEngine is led by President & CEO Hong-Ren Wang, Ph.D., and Chairperson Jan-Yau Hsu. The company markets ONIVYDE® (liposomal irinotecan), a topoisomerase I inhibitor approved in over 50 countries for metastatic pancreatic cancer in both second-line (post-gemcitabine) and first-line (NALIRIFOX regimen) settings.

Revenue is generated primarily through royalties and milestone payments from licensing partners Ipsen (US/Canada commercialization) and Servier (global ex-US/Canada/Taiwan commercialization), supplemented by direct product sales in Taiwan through PharmaEngine's own sales organization and an exclusive Taiwan distribution arrangement for LIPORAXEL® (oral paclitaxel) with Haihe Biopharma. In February 2025 the company received a US$50 million milestone payment from Ipsen after ONIVYDE's 2024 sales in Europe and Asia triggered the second sales milestone. The R&D pipeline comprises PEP07, a brain-penetrant CHK1 inhibitor licensed from Sentinel Oncology (UK) currently in Phase I for hematologic cancers (AML, MCL) and solid tumors, and PEP08, a second-generation MTA-cooperative PRMT5 inhibitor discovered via XtalPi Holdings' AI- and robotics-powered platform that began Phase I dosing in October 2025 as PharmaEngine's first internally developed clinical asset. A second synthetic lethality program has been initiated under the expanded XtalPi partnership.

The company holds 19 in-licensed invention patents plus 1 independently granted patent and 9 pending applications, along with 14 registered trademarks. PharmaEngine is ISO 27001:2022 certified (renewed January 2026), complies with GMP/GDP/GLP/GCP quality frameworks, and operates under a board structure with representatives from the Taiwan National Development Fund, TTY Biopharm, and independent directors with government and academic backgrounds. In 2025 the company was recognized among Taiwan's Best-In-Class companies by the Taiwan Institute of Directors, ranking first in Top 10 Profit Champions and second in Top 10 Growth Companies.

PharmaEngine Inc firmographics

Firmographics
Name
PharmaEngine Inc
Legal name
PharmaEngine Inc.
Website
https://pharmaengine.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
PharmaEngine Inc. is a Taiwan-listed virtual biopharmaceutical company that develops and commercializes precision oncology therapies, anchored by the global ONIVYDE franchise (liposomal irinotecan, approved in 50+ countries for metastatic pancreatic cancer) and an emerging pipeline of PRMT5 and CHK1 inhibitors.
Ownership category
akta.pro rank

PharmaEngine Inc industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Oncology drug development
  • Precision cancer therapies
  • Liposomal drug delivery
  • Synthetic lethality research
  • Virtual pharmaceutical company

Where PharmaEngine Inc is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices1 record

Markets served

PharmaEngine Inc business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. ONIVYDE Royalties and Milestone Payments: PharmaEngine receives royalties and milestone payments from licensing partners Ipsen (US/Canada) and Servier (global markets excluding US, Canada, Taiwan) based on ONIVYDE sales and achievement of development/regulatory milestones. In 2025, PharmaEngine received US$50 million milestone payment for ONIVYDE's 2024 sales in Europe and Asia reaching the second sales milestone.
  2. ONIVYDE Product Sales (Taiwan): PharmaEngine handles direct commercialization of ONIVYDE in Taiwan, generating product revenue through its own sales and marketing efforts.
  3. LIPORAXEL Distribution (Taiwan): PharmaEngine holds exclusive distribution rights for LIPORAXEL (paclitaxel oral solution) in Taiwan, handling local NDA filing, sales, and marketing, creating an additional product revenue stream.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

PharmaEngine Inc product offering

Product offering

Core offering

PharmaEngine develops and commercializes precision oncology therapies using a Virtual Pharmaceutical Company model. Its commercial product ONIVYDE® is a liposomal irinotecan formulation approved in 50+ countries for metastatic pancreatic adenocarcinoma. The pipeline includes PEP07 (CHK1 inhibitor, licensed from Sentinel Oncology) and PEP08 (first in-house developed PRMT5:MTA inhibitor, co-developed with XtalPi's AI platform), both in Phase I trials. PharmaEngine also distributes LIPORAXEL® (oral paclitaxel) in Taiwan.

Product overview

PharmaEngine Inc operates as a Virtual Pharmaceutical Company focused on oncology drug development and commercialization. The company's portfolio consists of one commercial product (ONIVYDE®) and multiple pipeline candidates in clinical development. ONIVYDE® is a liposomal irinotecan formulation for pancreatic cancer treatment marketed globally through partnerships with Ipsen and Servier. The R&D pipeline includes PEP08, a first-in-house developed PRMT5 inhibitor targeting MTAP-deleted cancers currently in Phase I trials, and PEP07, an oral CHK1 inhibitor licensed from Sentinel Oncology also in Phase I trials for hematological and solid tumors. Additionally, PharmaEngine distributes LIPORAXEL® (paclitaxel oral solution) in Taiwan under a partnership with Haihe Biopharma.

Differentiator

Problem solved

Functional benefit

Products and services

  • ONIVYDE® (Irinotecan liposome injection) Liposomal formulation of irinotecan (a topoisomerase I inhibitor) encapsulated in nanoparticles that accumulate in tumors and release the drug slowly. Approved for treatment of metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin after disease progression following gemcitabine-based therapy (second-line) and as first-line therapy in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen). Marketed globally through partners Ipsen (US/Canada) and Servier (rest of world) and directly by PharmaEngine in Taiwan.
  • PEP08 (PRMT5:MTA inhibitor)

Quantifiable outcome

  • NAPOLI-3 Phase III trial: NALIRIFOX showed statistically significant improvement in overall survival (median OS 11.1 vs 9.2 months, HR=0.83, p=0.04) and progression-free survival (median PFS 7.4 vs 5.6 months, HR=0.69, p<0.0001) versus nab-paclitaxel+gemcitabine in previously untreated metastatic PDAC
  • +2 more outcomes

Companies that use PharmaEngine Inc

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

PharmaEngine Inc technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

PharmaEngine Inc partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • XtalPi HoldingscoreTechnology or Integration · 1 June 2025XtalPi and PharmaEngine partnership enabled discovery of PEP08, a next-generation PRMT5 inhibitor using XtalPi's AI- and robotics-powered platform. PEP08 received clinical clearance in June 2025 and began enrollment in Phase I solid tumor trial in October 2025. Partnership has expanded to initiate a second synthetic lethality project targeting a different undisclosed mechanism. XtalPi reported RMB 802.6 million revenue in 2025 (201.2% increase) driven by collaborations including the PharmaEngine partnership.
  • Haihe Biopharma / Shanghai RMX Biopharma Co. Ltd.minorChannel Partner/ Reseller/ Distributor · 4 November 2024PharmaEngine entered an exclusive distribution agreement for LIPORAXEL (paclitaxel oral solution) in Taiwan. PharmaEngine is solely responsible for NDA filing, sales, and marketing of LIPORAXEL in Taiwan. LIPORAXEL is developed by Daehwa Pharmaceutical (South Korea) using DH-LASED drug delivery platform and distributed in Taiwan through Haihe's subsidiary Shanghai RMX Biopharma.
  • ServiercoreChannel Partner/ Reseller/ Distributor · 1 March 2024Servier is responsible for global commercialization of ONIVYDE outside of US, Canada, and Taiwan. In March 2024, Servier obtained EMA CHMP positive opinion and Taiwan TFDA approval for ONIVYDE NALIRIFOX as first-line treatment for metastatic pancreatic adenocarcinoma. PharmaEngine receives royalties and milestone payments from Servier's sales outside Taiwan.
  • IpsencoreChannel Partner/ Reseller/ Distributor · 13 February 2024Ipsen holds exclusive commercialization rights for ONIVYDE in the US and Canada for current and all potential future indications. On February 13, 2024, Ipsen received US FDA approval for ONIVYDE (NALIRIFOX) as first-line treatment for metastatic PDAC. PharmaEngine receives royalties and milestone payments from Ipsen based on net sales and achievement of development milestones.
  • Sentinel Oncology LimitedcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2022PharmaEngine exercised option for worldwide exclusive license for PEP07 (CHK1 inhibitor) from Sentinel Oncology in September 2022. PEP07 is undergoing Phase I clinical trials for hematologic cancers (AML, MCL) and solid tumors. Sentinel Oncology eligible to receive up to US$140.5 million in upfront, development, regulatory and sales milestones plus tiered royalties on worldwide net product sales.
  • NanobiotixminorOEM/ Whitelabel/ Licensing Partner · 5 March 2021Partnership for PEP503 (NBTXR3) in Asia-Pacific was terminated in March 2021. PharmaEngine granted back to Nanobiotix exclusive rights for development and commercialization of NBTXR3 in Asia-Pacific region. PharmaEngine is entitled to receive US$12.5 million in milestone payments and tiered royalties on net product sales in the region upon achievement of certain milestones.
  • Daehwa Pharmaceutical Co. Ltd.minorOEM/ Whitelabel/ Licensing Partner · 1 January 2017Daehwa Pharmaceutical (South Korea) developed LIPORAXEL using its DH-LASED (Lipid Self-Emulsified Drug Delivery) technology platform. Shanghai RMX Biopharma (Haihe subsidiary) in-licensed rights for development, manufacturing, and commercialization in China, Taiwan, Hong Kong, and Thailand. PharmaEngine holds exclusive distribution rights for Taiwan.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

PharmaEngine Inc competitors and assessment

Company assessment

Broad incumbents

  • Ipsen: Ipsen is PharmaEngine's exclusive commercialization partner for ONIVYDE in the US and Canada and a broader specialty oncology incumbent. Both companies operate in the same oncology pharmaceutical space and have a direct economic relationship through ONIVYDE royalties and milestones.
  • Servier: Servier is PharmaEngine's global commercialization partner for ONIVYDE outside the US, Canada, and Taiwan, and is a major European pharmaceutical company with significant oncology operations. Both companies share direct economics on ONIVYDE sales outside the named territories.
  • PharmaMar: PharmaMar is a European specialty oncology biopharmaceutical company developing and commercializing marine-derived oncology drugs. Both companies are specialty oncology players relying on licensing/partnerships for global reach.

Direct peers

  • Nuvectis Pharma: Nuvectis Pharma is a US clinical-stage precision oncology company developing a PRMT5 inhibitor (NUV-1516) for MTAP-deleted and other cancers. It is a direct competitor to PharmaEngine's PEP08 in the same target class and indication.
  • Cardiff Oncology: Cardiff Oncology is developing onvansertib, a CHK1/PLK1 inhibitor, in metastatic colorectal and other cancers. It is a direct competitor to PharmaEngine's PEP07 in the CHK1 inhibitor space and a similarly-sized clinical-stage oncology company.
  • IDEAYA Biosciences: IDEAYA Biosciences is a clinical-stage synthetic lethality and precision oncology company developing MAT2A and PRMT5 inhibitors (e.g., IDE397) for MTAP-deleted tumors. It is a direct competitor to PharmaEngine's PEP08 in the synthetic lethality oncology space.
  • Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage company developing a synthetic lethality platform targeting chromatin regulatory biology in oncology, including programs potentially relevant to PRMT5/MTAP biology. It is comparable to PharmaEngine's synthetic lethality R&D focus.
  • Repare Therapeutics: Repare Therapeutics is a clinical-stage precision oncology company building a synthetic lethality platform targeting DDR and related mechanisms (e.g., PKMYT1, ATR). Its synthetic lethality and DDR focus is directly comparable to PharmaEngine's PEP07 (CHK1/DDR) and PEP08 (synthetic lethality) programs.

Regional players

  • TTY Biopharm: TTY Biopharm is a Taiwan-based specialty pharmaceutical company with oncology and specialty drug operations and is a meaningful shareholder in PharmaEngine. It is a regional Taiwan peer with overlapping cancer drug distribution and development interests.

Others

  • XtalPi Holdings: XtalPi is PharmaEngine's strategic partner for AI- and robotics-powered small-molecule discovery that produced PEP08. It is an enabling/technology peer — comparable not as a competitor but as a closely tied discovery collaborator in the AI-enabled drug discovery ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

PharmaEngine Inc social profiles

Digital presence

PharmaEngine Inc compliance and trust

Trust signal

Compliance2 records

PharmaEngine Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaEngine Inc leadership team

Management profile

Number of profiles

Profiles18 records

PharmaEngine Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaEngine Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaEngine Inc

What does PharmaEngine Inc do?

PharmaEngine develops and commercializes precision oncology therapies using a Virtual Pharmaceutical Company model. Its commercial product ONIVYDE® is a liposomal irinotecan formulation approved in 50+ countries for metastatic pancreatic adenocarcinoma. The pipeline includes PEP07 (CHK1 inhibitor, licensed from Sentinel Oncology) and PEP08 (first in-house developed PRMT5:MTA inhibitor, co-developed with XtalPi's AI platform), both in Phase I trials. PharmaEngine also distributes LIPORAXEL® (oral paclitaxel) in Taiwan.

Is PharmaEngine Inc a public or private company?

PharmaEngine Inc is a public company. It is classified as public and is currently operating.

When was PharmaEngine Inc founded?

PharmaEngine Inc was founded in 2003. It employs 11 to 50 people.

Where is PharmaEngine Inc based?

PharmaEngine Inc is headquartered in Taipei, Taiwan, in the Asia region.

How does PharmaEngine Inc make money?

Three revenue lines are on record. ONIVYDE Royalties and Milestone Payments are the primary driver. The others are ONIVYDE Product Sales (Taiwan) and LIPORAXEL Distribution (Taiwan).

Who are PharmaEngine Inc's main competitors?

Broad incumbents on record are Ipsen, Servier and PharmaMar. Direct peers are Nuvectis Pharma, Cardiff Oncology, IDEAYA Biosciences, Foghorn Therapeutics and Repare Therapeutics. TTY Biopharm is listed as a regional player. XtalPi Holdings is listed as an others.

Does PharmaEngine Inc have an API?

No public API is recorded for PharmaEngine Inc.

What industry is PharmaEngine Inc in?

PharmaEngine Inc's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACXtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program UnderwayXtalPi and PharmaEngine announced that PEP08, a PRMT5 inhibitor, began Phase I solid tumor trial enrollments. The molecule targets MTAP-deleted tumors, which occur in 10-15% of cancers, and a second synthetic lethality project is underway. The global synthetic lethality market is projected to grow from $4.2B to $17.6B by 2033.Taiwan-HealthcareSalary 2021: Non-Managerial Employees in Taiwan’s Biomedical Sector|Institute for Biotechnology and Medicine Industry│IBMIAccording to MOPS Taiwan data for 2021, the average salary for non-managerial employees in Taiwan's biomedical sector decreased by 0.2% to 728K TWD among public companies, while OTC companies saw a 1.6% increase to an average of 771K TWD. Sixteen specific companies were identified as having annual salaries exceeding 1 million TWD, with PharmaEngine leading the OTC cohort at 2.03M TWD.BioWorldPharmaengine inks partnership with Sentinel Oncology for checkpoint kinase 1 inhibitor SOL-578Pharmaengine signed a collaboration and licensing deal with Sentinel Oncology for the checkpoint kinase 1 inhibitor SOL-578. Sentinel will receive an exclusivity payment, and Pharmaengine will fund the IND-enabling studies.PR NewswirePharmaEngine, Inc. y Sentinel Oncology Limited llegan a un acuerdo de colaboración exclusivoPharmaEngine, Inc. and Sentinel Oncology Limited have entered into an exclusive collaboration and licensing agreement for SOL-578, a Chk1 inhibitor developed by Sentinel. Under the terms of the deal, PharmaEngine will fund IND-enabling studies and holds an option to acquire worldwide development and commercialization rights upon successful completion.PR NewswirePharmaEngine, Inc. et Sentinel Oncology Limited concluent une entente exclusive de collaboration et de licence pour le produit SOL-578, un inhibiteur de Chk1PharmaEngine, Inc., a commercial-stage oncology company headquartered in Taipei, Taiwan, announced a collaboration and licensing agreement with Sentinel Oncology Limited of the United Kingdom to advance the development of SOL-578, a first-in-class checkpoint kinase 1 (Chk1) inhibitor targeting the DNA damage response network. Under the terms, PharmaEngine will fund preclinical studies and receives an option for exclusive worldwide development and commercialization rights, while Sentinel Oncology receives an exclusivity payment, development milestone payments, and tiered royalties on future net sales. The collaboration leverages PharmaEngine's experience with its approved drug Onivyde® to accelerate SOL-578 toward clinical development.PR NewswirePharmaEngine, Inc. und Sentinel Oncology Limited schließen eine exklusive Kooperations- und Lizenzvereinbarung für SOL-578, einen Chk1-InhibitorPharmaEngine, Inc., a Taiwanese oncology company, entered into an exclusive collaboration and license agreement with the UK-based Sentinel Oncology Limited to advance the development of SOL-578, a Checkpoint Kinase 1 (Chk1) inhibitor targeting the DNA Damage Response network in cancer cells. Under the deal, PharmaEngine will finance IND-enabling studies and gains an exclusive option to obtain worldwide development and commercialization rights for SOL-578, while Sentinel Oncology receives an exclusivity payment, upfront and development milestone payments, plus tiered royalties on future global net sales. The agreement positions PharmaEngine to leverage its experience with the liposomal irinotecan product Onivyde® to accelerate SOL-578's progression toward clinical development.PR NewswirePharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitorPharmaEngine, Inc. has entered into an exclusive collaboration and license agreement with UK-based Sentinel Oncology Limited to advance SOL-578, a best-in-class Checkpoint Kinase 1 (Chk1) inhibitor targeting the DNA Damage Response network in cancers. Under the deal, PharmaEngine will fund IND enabling studies and gains an option for exclusive worldwide development and commercialization rights, with Sentinel Oncology eligible to receive exclusivity payments, upfront fees, development milestones, and tiered royalties upon exercise. The collaboration leverages PharmaEngine's experience with Onivyde® and reflects strategic interest in Chk1 inhibitors as a novel approach for treating cancers with high replication stress.The Pharma LetterBRIEF—PharmaEngine inks deal with Sentinel Oncology for SOL-578PharmaEngine signed an exclusive worldwide licensing agreement with Sentinel Oncology for the checkpoint kinase inhibitor SOL-578. PharmaEngine will fund IND-enabling studies and pay an upfront payment plus development milestones and tiered royalties. The company aims to accelerate development based on its experience with Onivyde.GlobeNewswireNanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in AsiaPharmaEngine dosed its first patient in a Phase I/II trial of Nanobiotix's NBTXR3 for head and neck cancers in Asia, targeting patients receiving chemoradiotherapy. The trial enrolls up to 42 patients, following a successful European trial. Nanobiotix plans to prepare registration studies in Europe, the US, and Asia.PR NewswirePharmaEngine Announces Initiation of Phase 1b/2 Trial of PEP503 (NBTXR3) in Head and Neck CancerPharmaEngine Inc. announced that the first patient has been dosed in a phase 1b/2 clinical trial of PEP503 (NBTXR3) for head and neck squamous cell carcinoma at Keelung Chang Gung Memorial Hospital in Taiwan. This study aims to determine the optimal dose, safety, and preliminary efficacy of PEP503 when combined with concurrent chemoradiotherapy. The company's partner, Nanobiotix, is concurrently conducting related studies to identify optimal dosing strategies for different patient populations.